Daily Medical Update

Hyperlipidemia (Primary prevention, statin alternatives)

Wednesday, February 4, 2026

🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the last 12 months.

1. Bempedoic Acid Reduces MACE by 23% in People with Obesity

J Am Heart Assoc (2025) – CLEAR Outcomes Subset Analysis (n=6,177)

Key Findings

  • MACE-4 reduction of 23% (HR 0.77) vs placebo over 40 months.
  • Significant reductions in MI (32%) and stroke (36%).
  • Placebo-corrected weight change of -0.9 kg (-2.3kg total for drug group) at 36 months.
  • Consistent reductions in hs-CRP (-23.2%) and LDL-C (-22.5%).

📋 Practice Implication: Bempedoic acid is a particularly high-value option for primary and secondary prevention in patients with comorbid obesity and statin intolerance.

2. Obicetrapib (CETPi) Reduces LDL by 38% and MACE beyond 6 months

J Am Coll Cardiol (2025) – Pooled Analysis (n=2,884)

Key Findings

  • LDL-C reduction of 37.8% vs 4.6% for placebo.
  • ApoB reduction of 21.7% and Lp(a) reduction of 32.5%.
  • Statistically significant reduction in coronary events (HR 0.45) in the second 6 months of treatment.

📋 Practice Implication: Obicetrapib is emerging as a potent oral alternative to PCSK9 inhibitors for non-statin LDL lowering.

3. PCSK9mAbs and Inclisiran Lead in Lp(a) Reduction

Atherosclerosis (2025) – Meta-analysis of 147 RCTs (n=145,314)

Key Findings

  • PCSK9mAbs: 29% reduction in Lp(a).
  • Inclisiran: 22% reduction.
  • Statins, Bempedoic Acid, Ezetimibe: No effect on Lp(a).

📋 Practice Implication: For patients with elevated Lp(a), prefer PCSK9 inhibitors or inclisiran as they provide ancillary Lp(a) lowering while statins do not.

4. Bempedoic Acid/Ezetimibe Combo Highly Cost-Effective

Am J Cardiovasc Drugs (2025) – Cost-Effectiveness Analysis

Key Findings

  • Fixed-dose combination (FDC) of bempedoic acid and ezetimibe: ICER of $40,317 per QALY.
  • Bempedoic acid monotherapy (list price): $166,830 per QALY.
  • Threshold usually accepted up to $150,000 per QALY.

📋 Practice Implication: Prescribing the fixed-dose combination provides the best "bang for the buck" in high-risk statin-intolerant patients.

💡 Summary

Evidence continues to solidify non-statin therapies for high-risk patients. Bempedoic acid shows robust MACE reduction especially in obesity, and its fixed-dose combination with ezetimibe is highly cost-effective. While triple therapy (statin+ezetimibe+bempedoic acid) is safe post-ACS, it may not significantly outperform dual therapy for immediate goal achievement. Notably, PCSK9 inhibitors and CETP inhibitors (Obicetrapib) provide the best Lp(a) reduction.

Generated from 75 PubMed abstracts · RCTs and Meta-analyses only

Next topic: Metabolic Syndrome (PCP diagnostic criteria and reversing IR)